Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enteritis | 10 | 2023 | 18 | 4.890 |
Why?
|
| Gastritis | 10 | 2023 | 31 | 4.810 |
Why?
|
| Eosinophilic Esophagitis | 11 | 2024 | 34 | 4.090 |
Why?
|
| Eosinophilia | 9 | 2023 | 35 | 3.930 |
Why?
|
| Eosinophils | 4 | 2024 | 38 | 1.980 |
Why?
|
| Desensitization, Immunologic | 6 | 2022 | 107 | 1.930 |
Why?
|
| Colitis | 2 | 2019 | 51 | 1.310 |
Why?
|
| Allergens | 4 | 2024 | 139 | 0.920 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2022 | 73 | 0.770 |
Why?
|
| Hypersensitivity | 2 | 2023 | 77 | 0.770 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 119 | 0.750 |
Why?
|
| Anaphylaxis | 2 | 2018 | 71 | 0.730 |
Why?
|
| Gastroenteritis | 1 | 2019 | 17 | 0.680 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 34 | 0.670 |
Why?
|
| Esophagus | 3 | 2024 | 84 | 0.660 |
Why?
|
| Acetazolamide | 1 | 2018 | 19 | 0.630 |
Why?
|
| Pseudotumor Cerebri | 1 | 2018 | 24 | 0.620 |
Why?
|
| Drug Hypersensitivity | 1 | 2018 | 36 | 0.620 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 162 | 0.610 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 225 | 0.600 |
Why?
|
| Drug Design | 1 | 2018 | 120 | 0.600 |
Why?
|
| Anticonvulsants | 1 | 2018 | 122 | 0.580 |
Why?
|
| Immunoglobulin E | 2 | 2016 | 92 | 0.570 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 448 | 0.560 |
Why?
|
| Food Hypersensitivity | 2 | 2017 | 100 | 0.530 |
Why?
|
| Immune Tolerance | 4 | 2022 | 95 | 0.520 |
Why?
|
| Schnitzler Syndrome | 1 | 2014 | 4 | 0.490 |
Why?
|
| Child | 15 | 2024 | 6824 | 0.480 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 75 | 0.460 |
Why?
|
| Humans | 28 | 2024 | 49827 | 0.450 |
Why?
|
| Peanut Hypersensitivity | 3 | 2022 | 88 | 0.450 |
Why?
|
| Mycobacterium fortuitum | 1 | 2013 | 6 | 0.450 |
Why?
|
| Macrolides | 1 | 2013 | 16 | 0.440 |
Why?
|
| Clarithromycin | 1 | 2013 | 37 | 0.430 |
Why?
|
| Milk Hypersensitivity | 2 | 2024 | 19 | 0.430 |
Why?
|
| Child, Preschool | 9 | 2024 | 3853 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 458 | 0.360 |
Why?
|
| Urticaria | 3 | 2015 | 18 | 0.360 |
Why?
|
| Infant | 8 | 2024 | 3551 | 0.350 |
Why?
|
| Proton Pump Inhibitors | 3 | 2024 | 84 | 0.350 |
Why?
|
| Asthma | 2 | 2023 | 283 | 0.340 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 460 | 0.320 |
Why?
|
| Adolescent | 6 | 2019 | 6340 | 0.320 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 222 | 0.320 |
Why?
|
| Female | 15 | 2024 | 26329 | 0.310 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5138 | 0.300 |
Why?
|
| Synbiotics | 2 | 2024 | 3 | 0.290 |
Why?
|
| Administration, Oral | 3 | 2022 | 423 | 0.270 |
Why?
|
| Male | 13 | 2024 | 25093 | 0.250 |
Why?
|
| Infant Formula | 2 | 2024 | 145 | 0.220 |
Why?
|
| Amino Acids | 2 | 2024 | 358 | 0.220 |
Why?
|
| Food Supply | 1 | 2023 | 91 | 0.210 |
Why?
|
| Outpatients | 1 | 2023 | 113 | 0.210 |
Why?
|
| Middle Aged | 6 | 2021 | 11997 | 0.200 |
Why?
|
| Adult | 7 | 2023 | 13160 | 0.190 |
Why?
|
| Young Adult | 3 | 2019 | 3936 | 0.190 |
Why?
|
| Injections, Subcutaneous | 2 | 2024 | 52 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 2179 | 0.180 |
Why?
|
| Biological Therapy | 1 | 2019 | 16 | 0.180 |
Why?
|
| Leukocyte Count | 1 | 2019 | 70 | 0.170 |
Why?
|
| Standard of Care | 1 | 2019 | 16 | 0.170 |
Why?
|
| Ulcer | 1 | 2019 | 22 | 0.170 |
Why?
|
| Erythema | 1 | 2019 | 38 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 89 | 0.170 |
Why?
|
| Double-Blind Method | 4 | 2024 | 674 | 0.170 |
Why?
|
| Colon | 1 | 2019 | 98 | 0.170 |
Why?
|
| Intestine, Small | 1 | 2019 | 109 | 0.160 |
Why?
|
| Stomach | 1 | 2019 | 80 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2019 | 6117 | 0.160 |
Why?
|
| Epinephrine | 2 | 2016 | 96 | 0.160 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2018 | 11 | 0.160 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2018 | 2 | 0.160 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2018 | 3 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 150 | 0.160 |
Why?
|
| Disease Management | 1 | 2019 | 174 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 636 | 0.150 |
Why?
|
| Biopsy | 1 | 2019 | 582 | 0.150 |
Why?
|
| Gastroesophageal Reflux | 1 | 2017 | 49 | 0.150 |
Why?
|
| Particulate Matter | 1 | 2017 | 52 | 0.150 |
Why?
|
| Inflammation | 1 | 2021 | 604 | 0.150 |
Why?
|
| Immunization | 1 | 2017 | 67 | 0.150 |
Why?
|
| Consensus | 3 | 2022 | 143 | 0.150 |
Why?
|
| Comorbidity | 1 | 2019 | 618 | 0.140 |
Why?
|
| Seasons | 1 | 2017 | 81 | 0.140 |
Why?
|
| Deglutition Disorders | 1 | 2017 | 77 | 0.140 |
Why?
|
| Sympathomimetics | 1 | 2016 | 21 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2018 | 219 | 0.140 |
Why?
|
| Incidence | 1 | 2019 | 1003 | 0.130 |
Why?
|
| Disaccharides | 1 | 2015 | 11 | 0.130 |
Why?
|
| Meat | 1 | 2015 | 55 | 0.130 |
Why?
|
| Environmental Exposure | 1 | 2017 | 200 | 0.130 |
Why?
|
| Flow Cytometry | 1 | 2018 | 470 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2019 | 1422 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2021 | 2344 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 673 | 0.130 |
Why?
|
| Celiac Disease | 1 | 2014 | 10 | 0.120 |
Why?
|
| Hypothyroidism | 1 | 2014 | 54 | 0.120 |
Why?
|
| Fever | 1 | 2014 | 117 | 0.110 |
Why?
|
| Amikacin | 1 | 2013 | 19 | 0.110 |
Why?
|
| Azithromycin | 1 | 2013 | 25 | 0.110 |
Why?
|
| Skin Tests | 1 | 2013 | 58 | 0.110 |
Why?
|
| United States | 2 | 2023 | 4838 | 0.110 |
Why?
|
| Arkansas | 1 | 2017 | 1967 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1036 | 0.090 |
Why?
|
| Aged | 2 | 2021 | 9272 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2022 | 942 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 467 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2021 | 2744 | 0.070 |
Why?
|
| Interleukin-13 | 1 | 2024 | 15 | 0.060 |
Why?
|
| Interleukin-4 | 1 | 2024 | 43 | 0.060 |
Why?
|
| Remission Induction | 1 | 2024 | 207 | 0.060 |
Why?
|
| Cattle | 1 | 2024 | 210 | 0.060 |
Why?
|
| Milk | 1 | 2024 | 85 | 0.060 |
Why?
|
| Spirometry | 1 | 2023 | 29 | 0.060 |
Why?
|
| Nutritional Status | 1 | 2023 | 140 | 0.050 |
Why?
|
| International Cooperation | 1 | 2021 | 44 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2023 | 205 | 0.050 |
Why?
|
| Health Promotion | 1 | 2023 | 271 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 1374 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2023 | 353 | 0.040 |
Why?
|
| Constipation | 1 | 2017 | 35 | 0.040 |
Why?
|
| Vomiting | 1 | 2017 | 74 | 0.040 |
Why?
|
| Diarrhea | 1 | 2017 | 91 | 0.040 |
Why?
|
| Histamine Antagonists | 1 | 2016 | 19 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 49 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 854 | 0.030 |
Why?
|
| Quality of Life | 1 | 2021 | 833 | 0.030 |
Why?
|
| Animals | 2 | 2024 | 13150 | 0.030 |
Why?
|
| Mass Screening | 1 | 2018 | 351 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 230 | 0.030 |
Why?
|
| Swine | 1 | 2015 | 391 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 553 | 0.030 |
Why?
|